Xvivo Perfusion AB (publ)

OM:XVIVO Stock Report

Market Cap: SEK 7.0b

Xvivo Perfusion Valuation

Is XVIVO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XVIVO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 735.98
Fair Value
70.0% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: XVIVO (SEK220.8) is trading below our estimate of fair value (SEK735.98)

Significantly Below Fair Value: XVIVO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XVIVO?

Key metric: As XVIVO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for XVIVO. This is calculated by dividing XVIVO's market cap by their current earnings.
What is XVIVO's PE Ratio?
PE Ratio62.4x
EarningsSEK 111.38m
Market CapSEK 6.96b

Price to Earnings Ratio vs Peers

How does XVIVO's PE Ratio compare to its peers?

The above table shows the PE ratio for XVIVO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average61x
VIMIAN Vimian Group
75.9x44.61%SEK 19.3b
ASKER Asker Healthcare Group
89.8x24.85%SEK 38.7b
SUS Surgical Science Sweden
56x32.54%SEK 7.9b
ARJO B Arjo
22.2x25.82%SEK 9.5b
XVIVO Xvivo Perfusion
62.4x45.31%SEK 7.0b

Price-To-Earnings vs Peers: XVIVO is expensive based on its Price-To-Earnings Ratio (62.4x) compared to the peer average (61x).

Price to Earnings Ratio vs Industry

How does XVIVO's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
XVIVO 62.4xIndustry Avg. 34.1xNo. of Companies7PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: XVIVO is expensive based on its Price-To-Earnings Ratio (62.4x) compared to the European Medical Equipment industry average (33.8x).

Price to Earnings Ratio vs Fair Ratio

What is XVIVO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XVIVO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio62.4x
Fair PE Ratio63.7x

Price-To-Earnings vs Fair Ratio: XVIVO is good value based on its Price-To-Earnings Ratio (62.4x) compared to the estimated Fair Price-To-Earnings Ratio (63.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XVIVO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 198.00
SEK 370.83
+87.29%
21.18%SEK 495.00SEK 240.00n/a6
Jul ’26SEK 287.20
SEK 446.00
+55.29%
15.13%SEK 520.00SEK 320.00n/a6
Jun ’26SEK 306.40
SEK 448.50
+46.38%
14.02%SEK 520.00SEK 335.00n/a6
May ’26SEK 319.20
SEK 448.50
+40.51%
14.02%SEK 520.00SEK 335.00n/a6
Apr ’26SEK 291.50
SEK 476.17
+63.35%
17.05%SEK 567.00SEK 325.00n/a6
Mar ’26SEK 444.00
SEK 518.67
+16.82%
8.84%SEK 567.00SEK 460.00n/a6
Feb ’26SEK 466.00
SEK 522.00
+12.02%
8.06%SEK 567.00SEK 480.00n/a6
Jan ’26SEK 489.00
SEK 538.17
+10.05%
7.79%SEK 584.00SEK 480.00n/a6
Dec ’25SEK 480.00
SEK 538.17
+12.12%
7.79%SEK 584.00SEK 480.00n/a6
Nov ’25SEK 448.00
SEK 545.67
+21.80%
6.26%SEK 584.00SEK 480.00n/a6
Oct ’25SEK 503.00
SEK 549.00
+9.15%
6.57%SEK 584.00SEK 480.00n/a6
Sep ’25SEK 533.00
SEK 549.00
+3.00%
6.57%SEK 584.00SEK 480.00n/a6
Aug ’25SEK 506.00
SEK 549.00
+8.50%
6.57%SEK 584.00SEK 480.00n/a6
Jul ’25SEK 418.00
SEK 440.00
+5.26%
13.89%SEK 520.00SEK 340.00SEK 287.206
Jun ’25SEK 440.00
SEK 408.00
-7.27%
12.02%SEK 468.00SEK 340.00SEK 306.406
May ’25SEK 379.00
SEK 408.00
+7.65%
12.02%SEK 468.00SEK 340.00SEK 319.206
Apr ’25SEK 275.00
SEK 382.60
+39.13%
9.01%SEK 425.00SEK 340.00SEK 291.505
Mar ’25SEK 280.50
SEK 382.60
+36.40%
9.01%SEK 425.00SEK 340.00SEK 444.005
Feb ’25SEK 284.50
SEK 389.60
+36.94%
7.81%SEK 425.00SEK 340.00SEK 466.005
Jan ’25SEK 329.50
SEK 377.00
+14.42%
16.34%SEK 450.00SEK 280.00SEK 489.005
Dec ’24SEK 273.00
SEK 363.75
+33.24%
17.10%SEK 450.00SEK 280.00SEK 480.004
Nov ’24SEK 231.00
SEK 371.67
+60.89%
18.84%SEK 450.00SEK 280.00SEK 448.003
Oct ’24SEK 274.50
SEK 391.67
+42.68%
11.53%SEK 450.00SEK 340.00SEK 503.003
Sep ’24SEK 289.50
SEK 391.67
+35.29%
11.53%SEK 450.00SEK 340.00SEK 533.003
Aug ’24SEK 323.00
SEK 376.67
+16.62%
7.22%SEK 405.00SEK 340.00SEK 506.003
Jul ’24SEK 303.50
SEK 376.67
+24.11%
7.22%SEK 405.00SEK 340.00SEK 418.003
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
SEK 370.83
Fair Value
40.5% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/28 14:26
End of Day Share Price 2025/07/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Erik CasselDanske Bank
Daniel AlbinDanske Bank